CMR Surgical

The Versius Surgical System is indicated for adult patients 22 years of age and older, eligible for soft tissue minimal access surgery, for cholecystectomy.

CMR Surgical and NVIDIA unveil Versius Plus simulation at SRS 2026, predicting surgical outcomes to support safer, more informed robotic surgery.

The CMR Surgical news page covers research, updates on Versius, and robotic surgery developments.

Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology.

FDA clearance marks an important milestone in expanding the indicated uses of Versius Plus in the United States.

Bart Wilms brings extensive legal and compliance experience in healthcare to his role as General Counsel & Chief Compliance Officer at CMR Surgical.

Basel Abou Jalala is Commercial Senior Vice President, General Manager MEA, APAC & LatAm. Basel brings almost 30 years of leadership.

Chris has over 20 years of experience in medical devices, including roles at Virtual Incision, Intuitive Surgical, and Globus Medical.

The company’s team focuses on improving patient outcomes through surgery.

The company’s founders questioned why many people lack access to minimal access surgery and sought to address this gap.

Versius is a modular & portable surgical robot designed to make it easier for hospitals and surgeons to give patients access to minimal access surgery.

CMR Surgical collects personal information only when voluntarily provided via registration or subscriptions.

The page details personal information collected during recruitment, including how it is used and shared.

Using the website and submitting information grants CMR Surgical permission to use details as outlined in the privacy notice.

Company policies and reports for CMR Surgical are available on this page.

CMR Surgical’s Mandatory Compulsory Statement according § 35 a GmbHG (Act on Limited Liability Companies).

Website terms and conditions for CMR Surgical.